Skip to content

48 hours Moisturizaton activity of Lacto Calamine light Moisturising gel Cream

A Clinical Study to Evaluate the 48 hours Moisturizaton potential of Lacto Calamine light Moisturising gel Cream - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/11/097523
Enrollment
32
Registered
2025-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Lacto Calamine light Moisturising gel Cream: Dose: Gently massage approx. 0.5 to 1.0 gm product over one block assigned for the product Route of Administration: Topical C

Sponsors

Piramal Pharma Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male or Female 18 to 45 with dry skin 2. Subjects willing to give written informed consent. 3. Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 5. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial)

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast-feeding, or planning to become pregnant during the study. 2. Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years, or any other confounding skin condition. 3. Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments of the product. 4. Have participated in any interventional clinical trial in the previous 90 days. 5. Have a known sensitivity to any of the constituents of the test product 6. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including corticosteroids. 7. Have not skin related issues

Design outcomes

Primary

MeasureTime frame
Change in hydrationTimepoint: T0min, T+5min, T+30min, T2hours, T+8hours, T+24hrs, T+48hrs

Secondary

MeasureTime frame
Change in TEWLTimepoint: T0min, T5min, T30min, T24hrs, T48hrs

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026